Tenax Therapeutics, Inc.

Release Summary

Tenax Therapeutics, Inc. (Nasdaq: TENX), today announced results of pre-IND meeting with the FDA for Phase 2 levosimendan clinical trial for PH-HFpEF.

Tenax Therapeutics, Inc.